New compound Fabimycin can protect against more than 300 drug-resistant bacteria
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
New compound Fabimycin can protect against more than 300 drug-resistant bacteria
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
New compound Fabimycin can protect against more than 300 drug-resistant bacteria.
As the bacteria that cause UTIs become increasingly resistant to many antibiotics, they are becoming increasingly difficult to treat.
In a study published in ACS Central Science, researchers report the discovery of a new molecule that inhibits drug-resistant bacteria in laboratory experiments and in mice with pneumonia and urinary tract infections.
According to the researchers, the compound Fabimycin could one day be used to treat severe bacterial infections in humans.
According to the Centers for Disease Control and Prevention (CDC), Gram-negative bacteria are a group of microorganisms that infect millions of people around the world, causing diseases such as pneumonia, urinary tract infections, and bloodstream infections.
These bacteria have robust defense systems, tough cell walls that keep most antibiotics out, and pumps that efficiently remove any antibiotics that get into the body, making them particularly challenging to treat.
These microbes may also mutate to evade multiple drugs. Also, the treatments that work are not very specific, which makes them also eradicate beneficial bacteria.
In response, Paul Hergenrother and colleagues wanted to engineer a drug that would penetrate the defenses of Gram-negative bacteria and treat infections while leaving other beneficial microbes intact.
The team started with an antibiotic that was active against Gram-positive bacteria.
They then made a series of structural modifications that they thought would allow it to work against Gram-negative strains.
One of the modified compounds, called Fabimycin, proved potent against more than 300 drug-resistant clinical isolates, while remaining relatively invulnerable against certain Gram-positive pathogens and some typically harmless bacteria that live in or on the human body. active.
In addition, the new molecule reduced the number of drug-resistant bacteria in mice with pneumonia or urinary tract infections to pre-infection levels or lower, and performed as well or better than existing antibiotics at similar doses.
The researchers believe these results suggest that Fabimycin could one day be an effective treatment for persistent infections.
New compound Fabimycin can protect against more than 300 drug-resistant bacteria
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
